243 related articles for article (PubMed ID: 23736031)
1. p28, a first in class peptide inhibitor of cop1 binding to p53.
Yamada T; Christov K; Shilkaitis A; Bratescu L; Green A; Santini S; Bizzarri AR; Cannistraro S; Gupta TK; Beattie CW
Br J Cancer; 2013 Jun; 108(12):2495-504. PubMed ID: 23736031
[TBL] [Abstract][Full Text] [Related]
2. A nanotechnological, molecular-modeling, and immunological approach to study the interaction of the anti-tumorigenic peptide p28 with the p53 family of proteins.
Coppari E; Yamada T; Bizzarri AR; Beattie CW; Cannistraro S
Int J Nanomedicine; 2014; 9():1799-813. PubMed ID: 24748790
[TBL] [Abstract][Full Text] [Related]
3. Interaction of an anticancer peptide fragment of azurin with p53 and its isolated domains studied by atomic force spectroscopy.
Bizzarri AR; Santini S; Coppari E; Bucciantini M; Di Agostino S; Yamada T; Beattie CW; Cannistraro S
Int J Nanomedicine; 2011; 6():3011-9. PubMed ID: 22162658
[TBL] [Abstract][Full Text] [Related]
4. Modelling the interaction between the p53 DNA-binding domain and the p28 peptide fragment of Azurin.
Santini S; Bizzarri AR; Cannistraro S
J Mol Recognit; 2011; 24(6):1043-55. PubMed ID: 22038811
[TBL] [Abstract][Full Text] [Related]
5. Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination.
Jia L; Gorman GS; Coward LU; Noker PE; McCormick D; Horn TL; Harder JB; Muzzio M; Prabhakar B; Ganesh B; Das Gupta TK; Beattie CW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):513-24. PubMed ID: 21085965
[TBL] [Abstract][Full Text] [Related]
6. p28, an anionic cell-penetrating peptide, increases the activity of wild type and mutated p53 without altering its conformation.
Yamada T; Das Gupta TK; Beattie CW
Mol Pharm; 2013 Sep; 10(9):3375-83. PubMed ID: 23952735
[TBL] [Abstract][Full Text] [Related]
7. A peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cells.
Yamada T; Mehta RR; Lekmine F; Christov K; King ML; Majumdar D; Shilkaitis A; Green A; Bratescu L; Beattie CW; Das Gupta TK
Mol Cancer Ther; 2009 Oct; 8(10):2947-58. PubMed ID: 19808975
[TBL] [Abstract][Full Text] [Related]
8. Interaction of the anticancer p28 peptide with p53-DBD as studied by fluorescence, FRET, docking and MD simulations.
Bizzarri AR; Moscetti I; Cannistraro S
Biochim Biophys Acta Gen Subj; 2019 Feb; 1863(2):342-350. PubMed ID: 30419285
[TBL] [Abstract][Full Text] [Related]
9. Binding of Amphipathic Cell Penetrating Peptide p28 to Wild Type and Mutated p53 as studied by Raman, Atomic Force and Surface Plasmon Resonance spectroscopies.
Signorelli S; Santini S; Yamada T; Bizzarri AR; Beattie CW; Cannistraro S
Biochim Biophys Acta Gen Subj; 2017 Apr; 1861(4):910-921. PubMed ID: 28126403
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study.
Lulla RR; Goldman S; Yamada T; Beattie CW; Bressler L; Pacini M; Pollack IF; Fisher PG; Packer RJ; Dunkel IJ; Dhall G; Wu S; Onar A; Boyett JM; Fouladi M
Neuro Oncol; 2016 Sep; 18(9):1319-25. PubMed ID: 27022131
[TBL] [Abstract][Full Text] [Related]
11. A cell penetrating peptide derived from azurin inhibits angiogenesis and tumor growth by inhibiting phosphorylation of VEGFR-2, FAK and Akt.
Mehta RR; Yamada T; Taylor BN; Christov K; King ML; Majumdar D; Lekmine F; Tiruppathi C; Shilkaitis A; Bratescu L; Green A; Beattie CW; Das Gupta TK
Angiogenesis; 2011 Sep; 14(3):355-69. PubMed ID: 21667138
[TBL] [Abstract][Full Text] [Related]
12. The ubiquitin ligase COP1 is a critical negative regulator of p53.
Dornan D; Wertz I; Shimizu H; Arnott D; Frantz GD; Dowd P; O'Rourke K; Koeppen H; Dixit VM
Nature; 2004 May; 429(6987):86-92. PubMed ID: 15103385
[TBL] [Abstract][Full Text] [Related]
13. Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53.
Wang L; He G; Zhang P; Wang X; Jiang M; Yu L
Mol Biol Rep; 2011 Jan; 38(1):229-36. PubMed ID: 20333547
[TBL] [Abstract][Full Text] [Related]
14. Raman Evidence of p53-DBD Disorder Decrease upon Interaction with the Anticancer Protein Azurin.
Signorelli S; Cannistraro S; Bizzarri AR
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31238511
[TBL] [Abstract][Full Text] [Related]
15. 14-3-3sigma exerts tumor-suppressor activity mediated by regulation of COP1 stability.
Su CH; Zhao R; Zhang F; Qu C; Chen B; Feng YH; Phan L; Chen J; Wang H; Wang H; Yeung SC; Lee MH
Cancer Res; 2011 Feb; 71(3):884-94. PubMed ID: 21135113
[TBL] [Abstract][Full Text] [Related]
16. Molecular basis of Pirh2-mediated p53 ubiquitylation.
Sheng Y; Laister RC; Lemak A; Wu B; Tai E; Duan S; Lukin J; Sunnerhagen M; Srisailam S; Karra M; Benchimol S; Arrowsmith CH
Nat Struct Mol Biol; 2008 Dec; 15(12):1334-42. PubMed ID: 19043414
[TBL] [Abstract][Full Text] [Related]
17. Structural basis of bacterial effector protein azurin targeting tumor suppressor p53 and inhibiting its ubiquitination.
Hu J; Jiang W; Zuo J; Shi D; Chen X; Yang X; Zhang W; Ma L; Liu Z; Xing Q
Commun Biol; 2023 Jan; 6(1):59. PubMed ID: 36650277
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic p28 peptide targets essential H1N1 influenza virus proteins: insights from docking and molecular dynamics simulations.
Sasidharan S; Gosu V; Shin D; Nath S; Tripathi T; Saudagar P
Mol Divers; 2021 Aug; 25(3):1929-1943. PubMed ID: 33575983
[TBL] [Abstract][Full Text] [Related]
19. A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours.
Warso MA; Richards JM; Mehta D; Christov K; Schaeffer C; Rae Bressler L; Yamada T; Majumdar D; Kennedy SA; Beattie CW; Das Gupta TK
Br J Cancer; 2013 Mar; 108(5):1061-70. PubMed ID: 23449360
[TBL] [Abstract][Full Text] [Related]
20. A 28-amino-acid peptide fragment of the cupredoxin azurin prevents carcinogen-induced mouse mammary lesions.
Mehta RR; Hawthorne M; Peng X; Shilkaitis A; Mehta RG; Beattie CW; Das Gupta TK
Cancer Prev Res (Phila); 2010 Oct; 3(10):1351-60. PubMed ID: 20841487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
